MARSI
Financiado
Disruptive technologies for effectively rehabilitating chronic ambulatory disabi...
Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder
(stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the...
Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder
(stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in
Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular diseases (4 million),
spinal cord injury (paraplegia and quadriplegia, 3 million) and spina bifida (3 million).
Neurological disorders affect the lower motor of the nervous system and share the progressive muscle weakness, which
lead to several walk disability, loss of autonomy and psychosocial consequences. Most therapeutic treatments are limited to
medicines and musculoskeletal rehabilitation programs, which are very expensive and limited to 15-30 min/week
rehabilitation sessions.
Active lifestyle is the most effective measure to restore the physical conditions. But the loss of muscle strength impedes the
ambulatory function. The need is for a device allowing them walking effortlessly and safely in the everyday life activities.
Based on our ARES technology, -the minimal functional unit providing synchronized joints-muscles mobility- Marsi Bionics
has developed powered orthoses for in-house rehabilitation of patients affected by muscle weakness disorders, showing a
product portfolio that covers the needs of a wide range of Neurological Disorders. Marsi products will be commercialized
under renting models allowing patients acquiring it for daily use. This technology will improve these patients life quality and
enlarge life expectancy by avoiding critical health complications of losing walking ability.
Marsi is strengthened by joining with a leading company in the current industrial market, ESCRIBANO. This alliance in the
frame of SME Phase 2 will speed up industrialization, overcome the certification barrier and minimize the time to market. As
a result, we expect to reach above 36M€ turnover in 2023 and 81 generated jobs.
ver más
Duración del proyecto: 36 meses
Fecha Inicio: 2018-02-12
Fecha Fin: 2021-02-28
Fecha Fin: 2021-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-02-28
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
MARSI BIONICS
2.1 (i) la investigación y desarrollo de dispositivos robóticos y sus tecnologías asociadas que asistan al movimiento de humanos, animales o...
Perfil tecnológico
TRL
4-5
260K
Perfil tecnológico
TRL
4-5
260K